Easywell Biomedicals, Inc. (TPEX:1799)
Taiwan
· Delayed Price · Currency is TWD 66.60
-0.90 (-1.33%)
Apr 2, 2025, 1:30 PM CST
Easywell Biomedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 540.44 | 271.63 | 178.9 | 197.28 | 267.65 | Upgrade
|
| Revenue Growth (YoY) | 98.96% | 51.84% | -9.32% | -26.29% | -25.64% | Upgrade
|
| Cost of Revenue | 241.04 | 100.91 | 102.58 | 146.85 | 183.69 | Upgrade
|
| Gross Profit | 299.4 | 170.72 | 76.31 | 50.43 | 83.96 | Upgrade
|
| Selling, General & Admin | 94.88 | 61.96 | 28.16 | 24.15 | 21.21 | Upgrade
|
| Research & Development | 274.33 | 271.5 | 209.41 | 238.14 | 221.61 | Upgrade
|
| Operating Expenses | 374.19 | 333.46 | 237.57 | 262.29 | 242.82 | Upgrade
|
| Operating Income | -74.79 | -162.74 | -161.26 | -211.86 | -158.86 | Upgrade
|
| Interest Expense | -21.16 | -19.26 | -17.25 | -16.08 | -16.07 | Upgrade
|
| Interest & Investment Income | 4.94 | 3.42 | 2.18 | 1.18 | 0.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.28 | 7.5 | 7.53 | -1.13 | -10.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.34 | 1.17 | 0.46 | 57.99 | 0.92 | Upgrade
|
| EBT Excluding Unusual Items | -88.39 | -169.91 | -168.34 | -169.91 | -184.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.16 | - | 0.07 | 0.01 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | - | - | 0.24 | 1.49 | Upgrade
|
| Other Unusual Items | -0.09 | - | - | - | - | Upgrade
|
| Pretax Income | -88.29 | -169.91 | -168.28 | -169.66 | -182.82 | Upgrade
|
| Income Tax Expense | 0.16 | 0.26 | 0.12 | 0.85 | 2.03 | Upgrade
|
| Earnings From Continuing Operations | -88.44 | -170.17 | -168.39 | -170.51 | -184.85 | Upgrade
|
| Net Income to Company | -88.44 | -170.17 | -168.39 | -170.51 | -184.85 | Upgrade
|
| Minority Interest in Earnings | -9.02 | 25.35 | 7.39 | 20.12 | 11.43 | Upgrade
|
| Net Income | -97.47 | -144.82 | -161 | -150.39 | -173.41 | Upgrade
|
| Net Income to Common | -97.47 | -144.82 | -161 | -150.39 | -173.41 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 114 | 114 | 106 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 114 | 114 | 106 | 93 | Upgrade
|
| Shares Change (YoY) | 5.03% | 0.05% | 7.48% | 14.08% | 21.77% | Upgrade
|
| EPS (Basic) | -0.81 | -1.27 | -1.41 | -1.41 | -1.86 | Upgrade
|
| EPS (Diluted) | -0.81 | -1.27 | -1.41 | -1.41 | -1.86 | Upgrade
|
| Free Cash Flow | -171.53 | -169.17 | -60.99 | -136.02 | -174.83 | Upgrade
|
| Free Cash Flow Per Share | -1.43 | -1.48 | -0.53 | -1.28 | -1.88 | Upgrade
|
| Gross Margin | 55.40% | 62.85% | 42.66% | 25.56% | 31.37% | Upgrade
|
| Operating Margin | -13.84% | -59.91% | -90.14% | -107.39% | -59.35% | Upgrade
|
| Profit Margin | -18.04% | -53.31% | -90.00% | -76.23% | -64.79% | Upgrade
|
| Free Cash Flow Margin | -31.74% | -62.28% | -34.09% | -68.95% | -65.32% | Upgrade
|
| EBITDA | -22.19 | -121.01 | -116 | -160.42 | -96.31 | Upgrade
|
| EBITDA Margin | -4.11% | -44.55% | -64.84% | -81.32% | -35.98% | Upgrade
|
| D&A For EBITDA | 52.6 | 41.73 | 45.26 | 51.45 | 62.55 | Upgrade
|
| EBIT | -74.79 | -162.74 | -161.26 | -211.86 | -158.86 | Upgrade
|
| EBIT Margin | -13.84% | -59.91% | -90.14% | -107.39% | -59.35% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.